EXECUTIVE INTERVIEWS

• J&J And Merck Detail How They Are Investing For Impact

  Two Big Pharma executives explain how their organizations are investing for impact.

• Women On Boards: How We Get From Here To There

  Even though females have “arrived” as biotech executives, there’s more to be done: serving as CEOs, advisors, and directors to help companies achieve their missions.

• The 5-Step Strategy That Saved Genmab From A Dire Outlook

  Jan G. J. van de Winkel, Ph.D., cofounder, president, and CEO since 2010, remembers when Genmab faced some pretty tough decisions.

• What 9 Biopharma Trendsetters Expect For 2020 – And Beyond

  Although AI, machine learning, and quantum computing will someday improve our ability to forecast the future, for now Life Science Leader continues to seek knowledge from a cross section of life sciences industry execs.

• Biotechs Will Make Music In The “Twenty-Twenties”

  Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.

• Competing Interests Complicate FDA Reform

  With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.

• Want To Know What 7 Biopharma Manufacturing Execs Expect for 2020 – And Beyond?

  Therapy designations and FDA approvals don’t mean much if the product can’t be manufactured at the level necessary to meet market demand. Here, a cross section of biopharma manufacturing executives offer their opinions on what to expect in biopharma manufacturing for 2020  and beyond.

• Challenges Facing The Cell And Gene Sector’s Regulation Landscape

  Here are the critical action items cell and gene therapy professionals should heed to keep pace with the sector’s ever-evolving regulations.

• Biosimilar Competition Is Here To Stay In 2020

  Though the U.S. hasn’t witnessed a biosimilar market explosion as many anticipated, uptake has slowly but surely been creeping upward. I’m far from alone in believing it’s too early to propose dismantling the biosimilar industry.

• Technology Advancements Spur Adoption Of Virtual Trials

  Virtual trials have been around for years, so why are they still met with skepticism? Clinical trial executives from Janssen and Astellas weigh in on this hot topic for 2020.

• 5 Biopharma Finance Experts On What To Expect In 2020 – And Beyond

  As politics, finance and biopharma seem forever intertwined, we sought the counsel of five biopharmaceutical industry financial experts toward helping you prepare for what to expect in 2020 – and beyond.

• How — And Why — John Oyler Built BeiGene

  We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may surprise you.

• From Medtech CEO To Impact Investor — Not Your Typical Retirement Plan

  Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.

• Program Strives For More Females On Pharma Boards

  In this first of a series of articles dedicated to the Women in Bio Boardroom Ready program, we discuss what the program entails and feedback from some previous participants.